04.05.23 -- Cell & Gene Best Of March

This article discusses quantifiable market trends, clinical developments, regulatory landscape analysis, and investment trends for cell and gene therapy companies in 2023.

This article examines in detail why the product-level drivers of uptake – including efficacy, burden of administration, and durability expectations – are crucial for maximizing revenue potential and market share, particularly in markets with multiple competitors.

Our recent Cell & Gene Live, Tackling Cell & Gene Therapies’ Top 3 Regulatory Impediments, featuring BridgeBio's Dr. Adora Ndu and REGENXBIO's Dr. Nina Hunter, delivered just under 60 minutes of exceptionally valuable information. We also know that your time is likely not your own, which is why we’ve broken down the full-length version into digestible segments that you can view on your own time.

This article describes the advantages of a system that can streamline the tech transfer process by enabling efficient drug development activities and process data collection.

Grow your understanding of how new developments in CRISPR gene therapy drugs and FDA guidance are affecting cell and gene therapy products.

To provide a smooth transition from the lab to a CDMO, there are important factors you must first understand and steps to take prior to searching for and engaging with an external partner.